Supervised Endoscopic Tele-controlled Intelligent Lithotripsy (SENTINEL-1)

April 21, 2026 updated by: NG Chi Fai, Chinese University of Hong Kong

A Feasibility Trial of a Novel Robotic System for Retrograde Intrarenal Surgery

This is a phase I feasibility study to investigate the use of a novel intelligent robotic retrograde intrarenal surgery (RIRS) platform. The TaloStone T1000 RIRS system can manipulate the flexible ureteroscope, with remote control of the instruments (laser fibre or basket) and ureteral access sheath movements. Beyond teleoperation, the TaloStone T1000 RIRS system integrates AI perception models and decision-making algorithms to enable the supervised autonomous execution of critical tasks within the RIRS workflow.

Study Overview

Status

Recruiting

Conditions

Detailed Description

I. Introduction

Retrograde intrarenal surgery (RIRS) has become a preferred method for the diagnosis and treatment of urological diseases, such as kidney stone removal. However, the complex urinary and limited visibility of existing endoscope lead to inefficient manipulation of flexible ureteroscopes. Besides, conventional flexible ureteroscopy requires repetitive manual manipulation, which often results in surgeon fatigue, mucosa injury from respiratory motion, and variable stone clearance rates, particularly in complex calyceal anatomies.

The research focuses on the development of an novel robotic system for RIRS, currently dubbed "TaloStone T1000". The robotic system platform consists of a surgeon control console, a multi-functional video cart, and patient-side robotic arm with fiber-optic-sensitized flexible ureteroscopy as shown in Fig. 1. The surgeon console with optimized design of ergonomics is equipped with haptic master devices for smooth and precise control of the robotic arm to manipulate the flexible ureteroscope as well as instruments, e.g., stone baskets and laser fibers. The system also supports seamless integration of multiple modalities, including pre-operative CT scans, intra-operative endoscopic videos, and fiber-optic sensing. Besides, the self-developed flexible ureteroscope is embedded with fiber optic sensors for real-time shape sensing, force estimation, and simultaneous intrarenal pressure control and temperature monitoring. Shape sensing enables precise navigation of the ureteroscope within the renal collecting system, and force estimation provides accurate feedback of tip contact interaction to the master devices on the surgeon control.

Moreover, AI algorithms are incorporated to assist in diagnostics and higher level of supervised surgical autonomy, thereby improving safety and efficiency. The investigators developed AI-powered diagnostics for stone sensing, laser fiber recognition, depth awareness, and CT-to-endoscopy localization. Based on the sensing results from AI-powered diagnostics, the investigators proposed a supervised framework that can automate repetitive procedures throughout in-sheath and ureter navigation, laser approaching, and laser trajectory planning. The entire operation is under supervision of the surgeon, who can use one trigger on the master device or footswitch to enable or disable the supervised automated features. The foot pedal of laser device remains to trigger laser emission by the surgeon for stone fragmentation, dusting, and pop-corning. The basic safety and essential performance of both hardware and software in the robotic system were developed under clinical standards and medical device regulations.

To date, a total of three cadaveric studies have been conducted using the robotic system. In August 2024, the investigators performed the first cadaver study of the robotic system at Prince of Wales Hospital (PWH), where user study of ergonomic manners and tele-operation control of stone treatment was investigated. The second and third cadaver studies, focusing on the AI-powered features of the robotic system, were completed at PWH in June and December 2025. Synthetic renal stones of around 3mm were retrogradely inserted to the renal collecting systems, with successful fragmentation via the robotic RIRS system using Holmium:YAG laser. Over 10 doctors from PWH and the Chinese University of Hong Kong, participated in the cadaver studies. The current system response, motion speed of the robotic system, and operations with ergonomic control console can satisfy the requirements of the doctors. In addition to the cadaver studies, the investigators have conducted a set of laboratory testing and experiments, validating its robustness and stability of the system.

Subsequent to successful cadaveric experiments, the investigators planned to further validate of the feasibility of the use of the system in clinical cases. In this study, the investigators aim to evaluate the robotic system's safety and feasibility in RIRS in a stage 1, proof of concept study that follows the concepts outlined in the IDEAL framework (Idea, Development, Exploration, Assessment, Long-term Study).

II. Methods

Aim

The aim of this study is to evaluate the feasibility and safety of performing RIRS using the TaloStone T1000 system.

Study Design

This is a prospective, single-arm study that will be conducted by investigators from The Chinese University of Hong Kong/Prince of Wales Hospital in the period from November 2025 to June 2026. The investigators are experts in endo-urological surgery and robot-assisted surgery. The study design follows the guidelines for stage 1 of the IDEAL framework. The study will be carried out in accordance with the Declaration of Helsinki of the World Medical Association and the International Conference on Harmonization - Good Clinical Practice.

The study information will be provided to subjects during a preoperative consultation by the investigators and the research staff. Subjects will be provided with approved informed consent explaining the study procedure, risks, assessments, and required compliance; and will be given ample time to make their decision regarding participation in the study.

Perioperative data and outcomes from all cases of those participating in the study will be reviewed by an independent Data and Safety Monitoring Committee (consisting two senior urologists not involved in this study) for safety and identification of serious perioperative complications (within 30 days after the surgery) as interim to safeguard study subjects. The Committee will make periodic recommendations to the study team on whether to continue, modify, or prematurely terminate the study. Any adverse events will also be immediately reported to the Clinical Research Ethics Committee of the hospital.

Reporting of this stage 1 study will follow the IDEAL Reporting Guidelines.

Study Type

Interventional

Enrollment (Estimated)

15

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Hong Kong, Hong Kong, 999077
        • Recruiting
        • Prince of Wales Hospital
        • Contact:
        • Contact:
        • Sub-Investigator:
          • Steffi Kar Kei Yuen, MBBS, FRCSEd

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion criteria

  1. Adult patients >18 years old
  2. Renal stone(s) less than 1cm 2cm in maximal length
  3. Clinically indicated for RIRS
  4. Willingness to participate as demonstrated by giving informed consent

Exclusion criteria

  1. Patients with no preoperative CT imaging available
  2. Patients who are not recommended to receive RIRS
  3. Severe concomitant illness that drastically shortens life expectancy or increases risk of therapeutic intervention
  4. Untreated active infection
  5. Un-corrected coagulopathy
  6. Presence of another malignancy or distant metastasis
  7. Emergency surgery
  8. Vulnerable population (e.g. mentally disabled, pregnant)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: RIRS arm
Use of the TaloStone T1000 RIRS system
Retrograde intrarenal surgery (RIRS) will be performed using the TaloStone T1000 RIRS system. Beyond teleoperation, the TaloStone T1000 RIRS system integrates advanced AI perception models and decision-making algorithms to enable the autonomous execution of critical tasks within the RIRS workflow. The AI-based vision models coupled with sensors in the fURS allow real-time scene understanding, depth perception, stone size estimation, pressure and temperature feedback, and object tracking - thus establishing a robust foundation for higher level of surgical autonomy. Under supervision by the surgeon, the TaloStone T1000 RIRS system can perform supervised navigation into the collecting system, actively track a target stone, dynamically target the laser fibre tip towards a stone, plan the laser fragmentation route, and perform scope withdrawal for stone suction with re-entry.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Success rate
Time Frame: Intra-operative
Successful RIRS by the robotic system, i.e. without conversion to conventional manual RIRS
Intra-operative

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Stone free rate
Time Frame: Within post-operative 1 month
  • by non-contrast computer tomography (NCCT) performed within 1 month of surgery
  • without residual stone fragments, or residual stone fragments <2mm
Within post-operative 1 month
Operative time
Time Frame: Intra-operative
  • total operative time (time from start of operation to the end of operation)
  • console time (from start of control of robotic system to end of control of robotic system)
  • robotic control time (defined as time spent manipulating the control for navigation)
  • robotic set-up time (from the moment the robot is pushed into the operating room to the moment the flexible ureteroscope is attached to the robot)
  • procedure time (total operative time - The robot set-up time)
  • lasing time
Intra-operative
Total laser energy used
Time Frame: Intra-operative
Laser energy in terms of kJ
Intra-operative
Total radiation dose during operation
Time Frame: Intra-operative
Radiation dose based on fluoroscopy readings
Intra-operative
Surgeon radiation exposure
Time Frame: Intra-operative
- by radiation dosimeter
Intra-operative
Length of hospital stay
Time Frame: During admission period (up to 30 days)
- days of stay as in-patient
During admission period (up to 30 days)
Post-operative pain
Time Frame: From immediately post-operatively to discharge (day 0 to day 1)
- by visual analogue scale, from 0-10 with 10 being the most pain
From immediately post-operatively to discharge (day 0 to day 1)
Post-operative complications
Time Frame: Within post-operative 30 days
By "Clavien-Dindo Classification"
Within post-operative 30 days
Surgeon questionnaires
Time Frame: Immediately post-operative, day 0
Completed the Subjective Mental Effort Questionnaire (SMEQ) to assess subjective during RIRS surgery.
Immediately post-operative, day 0
Surgeon questionnaires
Time Frame: Immediately post-operative, day 0

Completed the System Usability Scale (SUS) questionnaire to assess the subjective usability of the robotic system during RIRS surgery.

The questionnaire uses a 1-5 scale, where 1 = Strongly disagree and 5 = Strongly agree.

Immediately post-operative, day 0
Surgeon questionnaires
Time Frame: Immediately post-operative, day 0

Completed the NASA Task Load Index (NASA-TLX) questionnaire to assess subjective mental and physical demand during RIRS surgery.

The questionnaire uses a 1-10 scale, where 1 = Very Low and 10 = Very High.

Immediately post-operative, day 0
Surgeon questionnaires
Time Frame: Immediately post-operative, day 0
Completed the Simulator Sickness Questionnaire (SSQ) to assess the subjective symptoms experienced during or after RIRS surgery. The questionnaire uses a 0-3 scale, where 0 = None, 1 = Slight, 2 = Moderate, 3 = Severe
Immediately post-operative, day 0
Surgeon questionnaires
Time Frame: Immediately post-operative, day 0
Completed the Likert Scales on Ergonomics and Comfort questionnaire, which assessed the subjective experience of minimal discomfort or fatigue during RIRS surgery. The questionnaire uses a 1-5 scale, where 1 = Strongly disagree and 5 = Strongly agree.
Immediately post-operative, day 0

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 15, 2026

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

March 31, 2027

Study Registration Dates

First Submitted

January 29, 2026

First Submitted That Met QC Criteria

February 11, 2026

First Posted (Actual)

February 13, 2026

Study Record Updates

Last Update Posted (Actual)

April 24, 2026

Last Update Submitted That Met QC Criteria

April 21, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code will be available.

IPD Sharing Time Frame

It will be available after the publication of the manuscript (latest 31 Dec 2027 by estimation), and will be available for up to 5 years afterwards

IPD Sharing Access Criteria

IPD will be shared in a de-identified manner for reasonable studies with approved from the relevant institutional review board.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • ANALYTIC_CODE
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Renal Stone

Clinical Trials on RIRS using the TaloStone T1000 RIRS platform

Subscribe